TransVision Madrid 2025 Summit

Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Greetings and welcome to the United States Transhumanist Party Virtual
Enlightenment Salon. My name is Jannati stolierof the second and
I am the Chairman of the US Transhumanist Party. Here
we hold conversations with some of the world's leading thinkers
in longevity, science, technology, philosophy and politics. Like the philosophers

(00:22):
of the Age of Enlightenment, we aim to connect every
field of human endeavor and arrive at new insights to
achieve longer lives, greater rationality, and the progress of our civilization.

Speaker 2 (00:39):
Aging is a natural process, but it's a process which
hurts our health and well being.

Speaker 3 (00:47):
We are lucky to have longevity researchers developing rejuvenation therapies.

Speaker 2 (01:17):
Welcome to Transvision twenty five.

Speaker 4 (01:27):
Our next speaker is President of Royal National Academy of
Medicine in Spain and a specialist in internal medicine and
medical oncology, leading Spanish medicine into the longevity era. And
he's truly had many prestigious precisions during his career. One
that also includes being appointed by the Spanish Ministry of

(01:48):
Health as head of the Comprehensive Cancer Plan. So please
give a warm welcome to mister Eduardo Diaz Rubio.

Speaker 5 (01:59):
Lucie.

Speaker 2 (02:01):
Did you lave of mine.

Speaker 6 (02:04):
Good evening?

Speaker 7 (02:05):
First of all, I will lie to sex and the
organizer with Cordeio Maria Cordon for inviting me to participate
in this very interesting meeting. This is really honor for me.
I will I also to congratulate because which Cordaido and
they would for the success of their book The Death

(02:27):
of Death, because he's a best seller in several continents.
I don't know how many editions they have, but anyway,
it is very remarkable. This is the second year that

(02:49):
I am here in this in this meeting. Last year
I I were here to present my book written in
Spanish Fili Immortality, A Journey to Work Immortality. The reason
why I wrote this book is because a young a
oncologist and so interested in concern cells. This book is

(03:15):
really an essay that blends history, science, ethic and pooturistic
speculation around immortality. I make an ANALYSI about the immortal cell,
especially to cancer cell, the healer cell that you know
very well.

Speaker 6 (03:34):
Whey of tying from a.

Speaker 7 (03:36):
Woman Andreeta Lacks in nineteen fifty one, and that is
really a great advance that produce a great benefit for
the humanity. There were the first immortal cells, but there
are all other like extern germinal cell. But on the contrary,

(03:59):
there are more mortal said, and the mortal said are
the somatic one.

Speaker 6 (04:04):
In this book I open.

Speaker 7 (04:06):
Also the door to the sentacence and the cloning, cellulary programming,
genetic edition, etc. With the clear objective the approach the longevity.
But today I am not here to talk about my book.
This is a figure that you know very well. The
life expectancy in Spain at the present time eighty four

(04:31):
years and in Madrid, in the region of Madrid eightys.
Being a woman eighty is eighty one for men, but
for many persons the age is a burden to have
it to wear. For this reason it is necessary to
remain that for who the most important is to add

(04:54):
life two years. In conclusion, we need to think about
a healthy life. So in this context it will be
important to approach the role of academics. The Royal National
Academy of Medicine in Spain RAM is a historical institutional
creative in nineteen eighty four, integrated in the Institute of

(05:19):
Spain with the American based academic body committed to medical science.
It's important to emphasize the values that is the independence, excellence, experience,
transversality and also meritocracy. So the question is what can
the academy do. I think that this is a good example.

(05:43):
The document Polish by the German National Academy of Science
Leopoldina recently in July twenty twenty five Anttailed healths Standing
Medicine in an aging society is focus on geoscience, providing

(06:03):
scientific reflection recommendation in the key areas basic research, clinical trials, aging,
biomarkers and regulatory framework. In summary, support the extrengsion of
healthy life beyond curing and treating diseases. So to ask

(06:24):
the question what can the our academy do in the
contexts of healthy life, I think that it will be
necessary to generate a statement or principle acts the LEOPOLDNA
do make a call to the society physician, researchers and
also decision maker.

Speaker 6 (06:45):
And for that what we need is to develop a project.

Speaker 7 (06:49):
We try to create a working group on geoscience a
working group. The objective and the principle of the group
are the following. Consolidate a multidisciplinary, translational academic forum between
the geoscience paradigm, having in mind that for us, geoscience

(07:11):
is the science of the biological mechanism of aging and
they link to the chronic disease. On the other hand,
the principle that could guide the project should be all
age is not a disease, but it isn't required roboscience.
As I said before, not just longer life, but better

(07:33):
life health span. But life is span and for that
what we need are clinical triers, robust clinical triers.

Speaker 6 (07:43):
In aging, not only in.

Speaker 7 (07:46):
Related diseases, and of course integrated molecular biology, clinical medicine,
artificial intelligence and public health. With this objective and principle,
the projects should be able to develop the following action.
First of all, establish a ROUN map for twenty twenty

(08:08):
six to twenty thirty.

Speaker 6 (08:11):
Create a working group.

Speaker 7 (08:12):
With internal an external member, excellent member spirits no more
than eight twelve expired and all the first academic workshop
heater science and Health in the second half of life.
And of course, produce a consensus paper focus on research recommendation,

(08:36):
a proposal of a pilot clinical trial. The definition of
a national genoscience strategy.

Speaker 6 (08:44):
I think that it.

Speaker 7 (08:45):
Is very important, and finally organize several themative wrong tail
words the wrong ta wars on Genoscience and health in
the second half of Life will focus on five critical
topics stable the biological basis of human aging, generoscience and
chronic diseases, current and future intervention, clinical and ethical dimension

(09:12):
on healthy long devity and public policies, Communication and medical education.
There are the five from table I mentioned before. The
first one biological basis of human age, sigi, olympathway, epigenetic
proteostasis and cellular and essence, Animal model and translation to humans.

(09:35):
The second one goule analyze the relationship between aging and cancer, diabetes,
cardiovacular disease, NAW the generation another for me, I have
seen that this isn't really a priority because we need
to control this disease, and finally try to answer the
question can we delay or prevent multiple diseases with the single.

Speaker 6 (10:00):
Intervention that there is a law aging.

Speaker 7 (10:03):
The third room table will focus on candidate drugs for
mean rapamicines and oalytic in cretis, not supplements induce pro
report and themselves advanced therapies analyze the outgoing studies on
trial and of course the role of diet, intermedient fasting, exercise, microbiota,

(10:27):
mitochondrial healths. The foreroom table focus on clinical and ethical
dimension on healthy longevity. Will consider precision and predictive medicine,
impact on health systems and equity in access to anti
aging therapid and also aging biomarket differentiating by biological from

(10:50):
chronological age. And finally, the feed and Room table will
be dedicated to public policies, communications and medical education, training
physicians in general science, the role of academic institution in
shaping a new vision of aging and also implications for
the longevity economy.

Speaker 6 (11:12):
In the final part, I would like to.

Speaker 7 (11:14):
Address a very sensitive fundamental issue for the development of
this project, the challenge and barriers, and in relation to that,
it is important to have the commitment of the institution,
it's academic member and also all the external SPA. Most
important is to get enough funding growing on national and

(11:36):
Agropeyan public funds, foundation and company with the eyeing of
holding working group, meeting, organizing roun table and produce document
and for that I think that it will be necessiety.

Speaker 6 (11:50):
To have a project manager in Gedero Science.

Speaker 7 (11:53):
As conclusion, I would like to state Spain needs a
national strategy genoscience. A AURA Academy can lead this project
with independence of jectivity and scientific excellence. The goal is
not just to live longer, but to live better in
good health. But remember that at present time these remained

(12:18):
a project that required approval and consolidation by the academic body,
and finally led me to emphasize for principles we cannot
renounce scientific regular and independence, multidisciplinary collaboration, orientation to God,
impact on paging and society, and open science and transparency.

(12:41):
To finish, I would like to remind you a phrase that,
in my opinion, might remain.

Speaker 6 (12:47):
In our minds.

Speaker 7 (12:49):
This phrase was written by Albill Toffler, a sociologist, writer
and food tourist, in his book Foodture Shock written in
nineteen benk where he said the illiterator of the twenty
one century will not be those who cannot read or write,

(13:10):
but those who cannot learn, unlearn and read them.

Speaker 6 (13:14):
Thank you very much for Duralda.

Speaker 8 (13:23):
Thank you, thank you so much to the President of
the Royal National Academy of Medicine O Spain. I'm so
proud that he's leading this important institution that on Friday
will also give an a word to doctor makemood. Can
I want to congratulate also ours. I love This report
can be distributed to the people here and to the

(13:44):
Major of Madrid, who is coming tomorrow. Okay, fantastic, So
we are going to give you the report.

Speaker 9 (13:50):
It's very nice.

Speaker 8 (13:51):
Well you saw his presentation and we will give it
tomorrow to the Major of Madrid and later also to
the President of the Community of Madrid. We are waiting
for the report of the Royal National Academy of Medicine
of Spain, so we will present that next year.

Speaker 10 (14:08):
Next year.

Speaker 8 (14:09):
Okay, Now let's continue with another doctor from Spain who
is part of the organizing committee of this event. So
we are very proud that Francisco Meda Cordeo has been
working with us for all this event and he has
been also coordinating the scientific part and he is doing
a fantastic presentation about longevity in Spain. He's an expert

(14:32):
on longevity, COVID and all of these things, and he
has eight minutes.

Speaker 11 (14:37):
Thank you, thank you very much, thank you very much
for ull my presentation with our slide and I'm going
to speak my experience and personal experience like a practice
on the refect the first after every one. Today is
a baby special way for me. It has being a

(15:00):
gr science. We begin the exiting of collaborating, of the
organization of this event, dreaming of the.

Speaker 5 (15:08):
Moment we will be heard together.

Speaker 11 (15:12):
My senior gratitude to the authoritives, presence for the super
and endorsurment. Thank you very much, lose the correct medicaulist,
especially to the doctoral Maria Cordon. To the media and
the press for influences and prefering these ideas that can
train the world. To the companies and investors whose commitments

(15:36):
bettal to turning the science to into reality. To the
brilliant community of anxiety arrested, who with their daily world
are based in the future of the linearity.

Speaker 5 (15:49):
And of course, to the general public, to all the you.

Speaker 11 (15:54):
Who, with your curiosity, energy and present give meaning to
the Gatari went to tradition twenty twenty five marriage. But
there is one thank you that deserves a very special
mention I want to be fans to for Siblisical.

Speaker 5 (16:10):
Know his starious role in leading is revolution.

Speaker 11 (16:13):
For the unique vision that of a engineer who say
the system of life and you manage you understand is
perform meaning has been and continues to be our compass
because you are autistic vision in Spain are all thank

(16:33):
you for giving us.

Speaker 5 (16:37):
In our precision unit you need.

Speaker 11 (16:42):
We have to put a compressive approach that moment begeon theoretic,
theorical models to clinical implementation. We employ a paganetic testing
to the terminal biological.

Speaker 5 (16:55):
Age of our passions so.

Speaker 11 (16:58):
They a metilation using macroom mio contal function to access
the sexual energy functions can do compressive myco analysis and
our little skank technology for real time make surement of
mineral status and toxic credit accumulations by analysis data.

Speaker 5 (17:20):
For all domains.

Speaker 11 (17:22):
We create a personalizic therapy for our passes in Spain.
In this moment, there are different laboratories companies Life dedicate
to creating personal sellum therapy protocols for longevity using compounds
center mutatium ad h cal coming a veratrol for impolving

(17:48):
the quality for getting off the health respland the biding
to the second crucial focus the essential connection between headers,
tank and sustainability. Throughout fine sports perform fin story represent
and revolutionary approach, but conating through that ecosystems all participant

(18:10):
air fauna FA and human that intelligence plain as for
sustainility is not that as log is a perform for
I understanding how human health intersect with planetary health. For
the place all other focus and involving CT is the
resort collaboration, collaboration in this position in Madrid III proteon

(18:33):
collaboration with the cboa with the to bono and I
n study about the scents and working for a production
basine in front of the face, for improving the healthy
span and for lack of of for high to try

(18:55):
nothing to disease. Okay, we are colluding. Peris relationship between
accett aging and ongoing our produce mating how fos bial
syndromes come primature aging process. We are for the place
nobody is vascination and you know that coul puson conscientously.

Speaker 5 (19:18):
Low aging process.

Speaker 11 (19:20):
This collaboration, they must a Mali role, a global hub
well clinical practice, sulstanity integration and glow breaking rassure converts
to create compressive solutions for healthy aging, but it has
emerged as the completed longuality court system. While multiples innovationsturing

(19:40):
is converted clinical substanity intergation rassure.

Speaker 5 (19:45):
We are emerging that the.

Speaker 11 (19:46):
Future longevity medicine must encompass not just personal time extension,
but also prietary sustaniity and cutting age.

Speaker 5 (19:57):
Racic collaboration transmition to any twenty.

Speaker 11 (20:00):
Five represent the perfect perform to advance this integration. We
are clinicians, resorts, data science and fulcinity experts can come
together to create compressive solutions for healthy aging of on
a healthy planet.

Speaker 5 (20:20):
Thank you very much.

Speaker 11 (20:21):
I look forward to our continue collaboration in building this
integrate future of longevity medicine.

Speaker 6 (20:29):
Thank you very much.

Speaker 8 (20:37):
Well, we have been working together, so I am so
happy that Francisco talked about that.

Speaker 10 (20:43):
Are really really fantastic.

Speaker 8 (20:44):
By the way, why you forgot to say something in
Madrid we say from Madrid to Heaven, the Madrid al Clo,
from Madrid to Heaven.

Speaker 5 (20:53):
Remember that.

Speaker 2 (20:54):
Yes, thank you.

Speaker 5 (20:56):
Okay, now we are ready.

Speaker 8 (20:59):
We are going to introduce George Church and for that
we have, of course our fantastic master of ceremony, Sabinida.
Soon Gaske, our.

Speaker 4 (21:09):
Next keynote speaker, is nothing more than a true legend
when it comes to geonomics and biotechnology. His innovations since
back in the early nineteen eighties have contributed to needing
all the next generation DNA sequencing methods and companies in
addition to his lab work on chip DNA synthesis, gene

(21:31):
editing and stem cells engineering. And this has all really
resulted in foundational application based companies spanning fields through all
through longevity and also medical diagnosis from crisper to synthetic biology.
Professor George church work has really reshaped what is possible

(21:52):
in science. And Professor George Church couldn't be here physically,
but we are so happy to have him here virtually.

Speaker 2 (22:01):
So mister George Church.

Speaker 4 (22:03):
I hand over the word to you a warm welcome
to Transvision Longevity Summit here in Madrid.

Speaker 12 (22:11):
It's a real pleasure to be at this Transvision twenty
twenty five in Madrid. I'm going to be talking about
what we call mL square for multiplex libraries plus AI
machine learning in particular and applying that to four different
kinds of therapies, protein, gene, cell and organ therapies. And

(22:33):
I'm going to produced in twenty minutes, so there's ten
minutes for Q and A. This is Longevity Day, October first,
and I have many thank yous along the way, but
in particular at the bottom here is Personal Genome Project.
Almost all the human subjects research, all the human tissues
and genomes or from the Personal Genome Project, and it's
your project.

Speaker 10 (22:53):
You can use it.

Speaker 12 (22:54):
It's freely available for commercial use if you want international
use fully consented. And here's my financial conflict of interest
in the lower right as a website. Okay, so I'm
going to quickly go through how we developed analytic and
synthetic tools, which you can think of as diagnostics and therapeutics,
and in particular we'll be focusing on gene therapist and

(23:15):
aging initially.

Speaker 10 (23:16):
So here's three examples of analytic tools.

Speaker 12 (23:20):
Antipore sequencers, alumina MGI fluorescent sequencers, and then spatial omix
that we've contributed to each of these things, and in
the process we've helped bring down the price of sequencing
and synthesis by twenty millionfold. And that includes moving from
a poor Human Genome Project goal which was just one

(23:40):
genome to two genomes diploid genomes in every human so
these are clinical grade in contrast, and now we have
nearly perfect genomes of six billion base payers per human.
Now that's the analytics side. On the synthetic and therapeutic side.
I just want to bring to your attention if you're
not all aware that there are affordable gene therapies, there

(24:01):
are also multimillion dollars per dose gene therapies that's mostly
for rare diseases, but at the common end. So this
is market size on the X axis and factors of
ten for the cost, it plummets down to about thirty
dollars a dose if you can get it to something
like these. COVID vaccines were all formulated as gene therapies
and hence six billion people benefited from them, and the

(24:24):
price could be come down. I think that's going to
be true for both pandemics and anything that evolves aging reversal.
And in addition to affordability, which is important to us,
we also want to have rapid feedback on the approval
process for use in humans, and we have two really
hopeful recent things. One was I was just alluding to
is the COVID gene therapy type formulation, which was a

(24:47):
brand new formulation, got eleven month FDA approval, which is
quite a bit better than the old days of ten years.
And then baby kJ went from a diagnosis a whole
genome sequence when he was born to seven months later
having a cure which has a name. The name of
the drug actually has his name built into a kJ

(25:08):
and the name of the editor abe a base editor
is a type of crisper that Musunura and Kieran and
his colleagues published in Doing the Journal of Medicine. Anyway,
I think that the gene therapies have this possibility of
doing things inexpensively and with rapid approval. Now, we wanted
to apply that to aging, and we didn't want to

(25:29):
make a assumptions about biomarkers and so forth.

Speaker 10 (25:31):
We wanted to look at actual diseases of aging, age
really disease.

Speaker 12 (25:35):
Now, their age related disease is going to kill ninety
percent of us, so it affects almost every disease. But
we wanted those that were considered really characteristic of aging.
We wanted to cure several different diseases at once to
show that we were really getting at the core of aging.
So we started with forty eight gen therapies here in
the upper right, and then focused in on three of
them in various combinations. So the three that we picked

(25:57):
were abbreviated AT and F for alpha clotho TGF beta
receptor in FGF twenty one, and they're color coded and
they're in this diagram, this cartoon of going from the
extracellular at the top through the bilayer the cellular signaling
to nuclear mitochondrial components, all of which have impact us
specifically aimed at aging signaling pathways.

Speaker 10 (26:21):
And we did that two triple therapies.

Speaker 12 (26:23):
The one is this one up at the extracellular so
it's being secreted into the blood like young blood is
known to be involved in aging. And then a triple
factor also famous from Nobel Prize Shina Yamanaka, which we
used three of the four factors abbreviated OS and K,
so AT and F and OS and K are our
three triple therapies that we finally got out of the

(26:45):
forty eight initial gene therapies that we tested. This is
mostly the work of Noah Davidson and all mentioned in
the next line. So we tested these with disease models
in animals and now we're moving into human clinical trials.
But we wanted to test as many diseases we could.
We started out with four, an how we're up to
eight or so. For example, high fat obesity, induction and

(27:07):
we can restore that to normal with one of the
combinations here or two of the combinations magenta in particular,
and then insolent tolerance for a diabetes model, and then
a kidney damage and restoration recovery. You can see the
day zero where it's not damaged, and then at the
end with two transcription factors T and F of the
AT and F. And this is Noah Davidson. He was

(27:29):
on these three papers, all of which used aav viral
delivery mechanism, and these two triple therapies and various subsets
of them.

Speaker 10 (27:38):
ATF and OSK.

Speaker 12 (27:40):
In addition to these papers, he and I started its company,
Rejuvenate Biome, which is bringing these into clinical trials, both
veterinary and human clinical trials. Now, we don't go to
the FDA talking about escape velocity or even longevity or.

Speaker 10 (27:54):
Deaging, even though that is what we're interested in.

Speaker 12 (27:56):
We talk about age related diseases, but we nevertheless part
of those studies we also do for our own edification,
not necessarily for FDA, not required for FDA approvals.

Speaker 10 (28:05):
We look for survival curves and I think these are
the gold standard.

Speaker 12 (28:09):
If you don't have a survival curve, it's not clear
that you're really working on longevity, maybe working on something
else of medical significance. But anyway, these survival curves, we
applied the drug very late in life. So some drugs
people feel that you might have to apply at a
very young age in order to prevent aging. But we
did this very old where half of the animals were
dying for natural longevity related causes. Nevertheless, when we apply

(28:34):
it that late in life, we still got a very
significant shift to the right. This is a blue line
which is treated in the black as the control. We're
seeing about a fifty percent extension from that point forward
from that very late stage FOARD and this was peer
reviewed in this cellulary programming paper two years ago. So
that's for juvenile pile And then here's another one, like

(28:54):
I said, the gold standard of these survival curves. And
here's a survival curve that was for OSK that was
one of our triple gene therapies. But we've also done
a single gene therapy completely unrelated to either of the
two triples I talked about from Juvenate. This is from
a company called Regular Bio that my student last well
was Noah Davidson. This is Alex Plesa published this paper,

(29:14):
and here is the lifespan effect, where we're seeing a
fourteen percent effect or so from the single gene, which
is equivalent in mouse years to human years. Is about
ten year human effect, and the same thing we see
about the same sort of delay and onset of fragility.
So you can see in these pictures the one on
the left is the control and the one on the
right is the animal treated with SRF one, which is

(29:37):
a splicing factor. So the OSK we're transcription factors, and
the ATF were all bloodborne liver produced protein, so different
mechanisms and we're getting you can see how this sparse hair,
gray hair, lots of fragility and grip strength and so forth.
Behind the scenes and all of this is a lot
of computing and AI, and I'll just give you an

(29:59):
insight into that. We feel that AI alone is not
giving us the answer, but when we combine it with
large libraries molecular libraries, they're kind of doing real world computing,
and the combination of the two is very powerful. So
we can actually deliver a million different designs. AI based designs.
They're not random they're not comminatory, they're independent AI designs.

(30:20):
Inject them into a primate as close to human as
we can get, and then we can test all the
tissue tropisms, all the different cell types that it goes to,
it's interaction with the immune system, and so forth. And
we can do this for a million at once, which
is very economical for whether we're doing rodent or primate.
Here we mutilize every position of the delivery vector, the

(30:42):
viral capsid protein at all seven hundred and some amino acids,
every possible substitution, where red means it's actually better at
wild type of delivering that particular tissue, and so we
can select for things that are more abundant in harder
kidney and low abundance in liver, which is easy to get.
Year five of the first successes that we had, and

(31:03):
I'll show you one in particular, BECAP one is one
hundred times better at brain stand instruction than the previous best.
So this is not relatives some random viral vector. This
is AV nine, which was the best way of delivering
to the brain before this study. We improved that one hundredfold.
You can see here on the far right and in
the process. We also detargeted deliver by tenfold, which means

(31:25):
we have to waste less money on the virus. We
also have lower toxicity because we use a lower dose
to get it delivered. Again, this was the combination of
machine learning to make the libraries and then the multiplex
libraries to find the best, the ones that got to
the brain the best. And we've done this for a
variety of different tissues, and we've done it in two
different species of primate to really make sure this is

(31:46):
going to be human relevant. This is thanks to Pierce
and Eric's published these two papers and co founded Dino
Therapeutics and have multiple collaborations on this. Just one last
point on the AI here is that if we use
a naive AI model or a random model, it's very
hard to make these large libraries. We can focus in

(32:06):
on a key surface region of the caps that's going
to determine where it goes, which tissue goes to, and
pick twenty eight amino acids in a row that are critical.

Speaker 10 (32:16):
If we take a naive model here.

Speaker 12 (32:18):
In the lower left, we can hardly get any successful
library members. But if we use logistic regression or some
neural nets, we can get twenty six, seven and twenty
eight out of twenty eight, essentially changing all the amino
acids and still have functioning virus. This gives us great diversity,
so we can get new functionality, meaning new delivery. In

(32:38):
this case, that's what we can do with viral capsis
for delivery. We can also do lipid nanoparticles if they
have surface properties that we can engineer, and the nucleic
acid is providing the barcode that tells us. That allows
us to know who the winners were. So when we
get a winner, we want to know what it may win,
and then we use the barcoes for that. But in
some cases we don't want to have a virus a

(33:00):
lipid nanoparticle. We want to have a simpler peptide or protein,
and for that we want to have a small, innocuous
non nucleic acid code. So here you can have a
protein or a short peptide of barcode. And these are
synthetic and we choose them so that we can easily
detect them. So here's showing our detecting signal along the
y axis and we can see very little off diagonal.

(33:22):
The diagonal is very strong. Here's a blow up of it.
We can make thousands of these barcodes with very clean
detection orthogonality with each other, so we can basically bar
code as many proteins as we want, and we can
use these for brain connectome and more importantly for Manifold
bio who championed this or got this to work to
help co found We get tissue specific medicines, so it's

(33:43):
like the capsin story, except now with proteins rather than
gene therapies. And here's an example where we got ten
thousand fold enrichment of one protein relative to random proteins
in this screen. This is a screen using a humanized
mouse having a human transferin receptor, and we showed that
we really needed to do this screen in vivo. So
again this is a combination of the AI machine learning

(34:06):
up front so that we get high diversity. But then
we tested millions at a time in vivo. So I
gave two examples of Dyno and Manifold for gene therapy
and protein therapy respectively. But we have lots of other
companies that have spun out of my lab Introde, the
Nabla helix, Nano Dura shape and Lila dot AI goes
beyond therapeutics to science in general. I'm very excited about

(34:30):
lila AI and many of these, essentially all of them
use this combination we call mL square for machine learning
plus multiplex libraries. Then the final topic and then we
who have time for questions. I hope is on sell
and organ therapies. We harnessed transcription factors and slicing factors.
As you've seen, we can harness them so we can
get up to ninety eight percent conversions from stem cells

(34:52):
to our target cells in just four days. That we
didn't know to expect that at the beginning, but it's
what we've seen is what we should expect. And if
we dot getting that, then we probably haven't worked hard
enough to get the right recipe. We have now three
hundred different recipes to get different cell types, and we
use RNA readouts, which is the one here where we
can classify them broadly as endothelial neurons or fibrilasser and

(35:14):
then we can do subcategorize each of those, for there's
different endothelial neurons depending on different parts of the body.
And so we have these three hundred recipes and then
a couple of them are making it now towards clinical trials.
Here's an example of one where we have a recipe
for making a ligod indercite precursor cells. These ligodendrocytes wrap

(35:34):
myelin around the axons to make rapid neural transmission that
you have in your white matter, and this is what's
demilinated in autoimmune diseases like multiple sclerosis. We want to
remilinate it, but we don't want it to succumb to
another round of autoimmune degradation, so we supply them not
only with this ability to remilinate, but also production of

(35:56):
cytokines which prevent the autommune attack. So these are a
certain sense supercells. They're better than the original cells. So
we're not just doing a transplant. We're actually making an
enhanced part of the brain that the white matter makes
about forty percent of your brain. This is a pretty
important thing to be getting control of. And autoimmunity resistance
is related to tolerance, which we've developed for transplants in general,

(36:19):
and you'll see that in a moment. A second tissue type,
so this is a ligand indercite tissue type with GES
therapeutics and then two other companies that came from two
of my graduate students here, Christian Kram and Merrick Smila, Caamto,
and Ovel are trying to make either mature oocytes in
the IVF clinics or make aches from scratch. The first

(36:41):
of these, the maturation, is now the first IPS based
therapy to be FDA approved, and it's now in phase
for your clinical trials. So this is looking very promising.
It allows us to reduce the number of hormone shots
from dozens II factor three and reduce the price bio
factor three as well. And finally, so those were tissue

(37:02):
types derived from human stem cells. But to get organs,
we haven't yet. No one has made really large organs
like kidney, heart, liver, and so forth. So to do
that we need a full developmental system that's as close
to human as is feasible. And so we chose pigs
in part because a number of groups before us saw
the value of pigs being close physiologically and anatomically in

(37:25):
size and so forth. And our first one is kidneys,
but we're also doing liver and heart. But for kidneys
we have hundreds of thousands of people on dialysis. It's
a very unpleasant experience. You're limited geographically where you can go,
and also there's a brain fog that many of them experienced.
It's just the toxicity is not completely alleviated by the dialysis.

(37:45):
We had a series of papers here largely spearheaded by
Mike blu Hanyang who was a gradu student and a
post doc and a co founder of Eugenesis with me
that we had to do three knockouts and seven knock ins,
as say, seven trans genes that humanize the pig for
all sorts of blood complement factors, blood clotting and aid immunity, inflammation,
and Moreover, the FDA was very worried about the indigenous retroviruses.

(38:10):
These are things that could cause cancer or other problems,
and in particular since all transplants, even human the human
involved immune suppression. If you have all the pigs overproducing
large amounts of these viruses in an immune suppressed patient,
that is a recipe for a very unwanted possible outcome
of evolving zoonotic virus. So the FDA didn't want that.

(38:33):
So we knock them all out using Crisper, and we
were invited by the field, essentially by three of the
founders that feel to apply our crisper methods to these
animals and multiplex editing. Really and we're not only trying
to address the worldwide shortage of sufficient donor organs, but
we were also trying to make enhance it similar to
that enhancement I was talking about before of making them

(38:54):
resistant to autommunity. We have animal examples of animals that
are resis distant to cold dehydration, to DNA damage, the
multiple pathogens cancer, and senessence. We're trying to transfer these
into the pig germline so that we can get better
and better organs for org considered, we better than you
can get from humans. So, for example, here's a list

(39:16):
of dozens of human specific pathogens which our pigs are
not susceptible to. We'd like to extend this list to
include all pathogens, but we're not there yet. This is
a video of our longest ZENO transplant so far. This
is this sixty nine edited pig kidney. You can see
the MGH surgeons transplanting it into Tim Andrews. And then

(39:37):
we have a second page. So Tim was in January,
so he was eight months and then Bill Stewart, another
new Hampshire man I was transferred in June and they're
both off dialysis and very happy about it. And I
just want to open it up for questions and thank
everybody again, thank the Personal Genome Project, which was the
inspiration and the source of the cells and the data

(39:58):
for a lot of the human experiments.

Speaker 10 (40:00):
And then this is somewhat lab alumni, so thank you,
doctor Jarber.

Speaker 8 (40:11):
We are so happy, thrilled to have you here, and
we are running out of time, so I just have
one question because I'm very interested also in the extension.
The extension you worked on the the wold, now the
next the mammoth. What is the potential of those technologies
for longevity.

Speaker 12 (40:31):
Yeah, so that project, the Colossal project, is an excellent
test bed for developing our developmental biology tools, and aging
is a component of developmental biology.

Speaker 10 (40:43):
Is an epigenetic program.

Speaker 12 (40:44):
Where rodents die about a year and bowhead whales live
for two hundred years, So it's genetics and epigenetics and
we're getting a lot of insight into that into rescuing
endangered species and other things that we're doing at costs. Also,
they're funding some of the work that we're doing on
new reproductive technologies I talked about in multiplex editing, which

(41:06):
I think is going to be key for all of
the gene therapies that we're talking about. We're using in
combinations in various sorts. That's you're can thinet as multiplex
gene therapies. So yes, it's very synergistic the projects we
do in Colossal and the other projects we do that
are now making in the human clinical trials.

Speaker 8 (41:23):
Thank you so much, and we wish you to win
the Nobel Prize in Medicine very soon.

Speaker 2 (41:30):
Doctor Charge.

Speaker 10 (41:33):
Good, Thank you for.

Speaker 4 (41:41):
So Our next keynote speaker is an experience knowledgeable and
well versed a doctor in the longevity sphere. Doctor Andrea
Meyer is a physician, scientist, the longevity doctor and founding
president of the Healthy Longevity Medicine Society and also founder
of Chi Longevity, and her work in Singapore and globally

(42:02):
is focused on bringing aging biology into clinical practice, really
transforming longevity from theory into medical reality.

Speaker 13 (42:11):
Please give it up for Andrea Meyer. I'm a guratorician.
Most of the times I say can you hear me?

Speaker 2 (42:22):
Can you see me?

Speaker 14 (42:23):
It seems to be all right now good. Thank you
so much for being here. A wonderful building whose thank
you so much. I think you asked me three times
and then I said, Okay, I cannot neglect you anymore.

Speaker 2 (42:34):
I have to come, and I'm really honored to be here.
You're really a.

Speaker 14 (42:39):
Magic figure, the star in this space, and not that
you want to be that star in the end, but
and you said that I do non political comments. I
think as Aubrey, I learned it. I think reform the best,
and that's aub degray to be sometimes not political. Sometimes
I can be political, so I can also serve you.

Speaker 2 (42:59):
In that way. But anyway, we are going from mice
to humans, and.

Speaker 14 (43:02):
I would love to tell you a little bit where
we are in this phase of precision gero medicine.

Speaker 2 (43:07):
Hence, up, who knows what precision gero medicine is? Okay?
A couple who knows what healthy longevity medicine is? Okay?

Speaker 10 (43:18):
Okay.

Speaker 2 (43:19):
So healthy longevity medicine is a new.

Speaker 14 (43:21):
Specialty within the medical arena to optimize the health and
health bold.

Speaker 2 (43:26):
From aging individuals.

Speaker 14 (43:27):
And I use the term with many of other colleagues
for five years now, and we were calling ourselves healthy
longevity medicine positions, and I always got the question, Andrea,
don't you have a Latin word like it's not sexy enough,
it's not attractive enough. And so we said, okay, I
had a good glass of wine Bisquito Chroma in lovely Paris,

(43:50):
and we said, okay, we have to change the wording,
and we came up with precision gero medicine. Why is this,
I think a good term because everybody knows what precision
medicine is. That's a new arena of medicine. So now
we are putting duro in front of it, and guro
is aging or age depends on which school you have,
and hence its position aging medicine. And hopefully we will

(44:12):
attract many more and also the FDA and the EMA
with this new term.

Speaker 2 (44:17):
I have a couple of disclosures.

Speaker 14 (44:19):
I'm quite proud to be the founding president of the
Health and Longevity Medicine Society. I also think that all
of us here should be a member of the Biomarcrosoft
Aging Concertium. And I'm also quite proud to be involved
in the Academy for Health and Lifespan Research. This is,
at least in theory, what we are doing at this
moment in time and a couple of countries.

Speaker 2 (44:40):
We're already doing that, and it's a framework.

Speaker 14 (44:42):
How do we bring all the knowledge of guroscience into
human studies, into clinical practice, and then into public health.
I fully agree with alb Degray saying we know enough,
let's translate because we're fixing mice and already showing that
and others too, that we actually can fix mice at
this moment in time, they can live twenty thirty percent longer.

(45:05):
So if we have that knowledge, how do we actually
transfer that into humans?

Speaker 2 (45:09):
And the time is ripe.

Speaker 14 (45:11):
Sixteen years ago I wrote my first business case while
I was working as an internal medicine specialist in Amsterdam UNC,
which is an academic clinic in hospital in the Netherlands.
I wrote the first business case for an early warning clinic,
which was then the term I thought for health's longevity
medicine clinic.

Speaker 2 (45:29):
It was hugely rejected, hugely say you are so stupid.

Speaker 14 (45:33):
Why should somebody look at me being healthy, come to
a clinic and do a check up.

Speaker 2 (45:39):
Now it changed. Now we have the translation and we
have randomized.

Speaker 14 (45:43):
Control trials and I will showcase your couple we are
doing and we can introduce that into clinics, and we
already did that in twenty twenty three in August in
Singapore we opened the first publicly funded longevity clinic in
a publicly funded hospital.

Speaker 2 (45:57):
It's occurring. The time is there are doing it, and
I think we will really revolutionize the.

Speaker 14 (46:02):
Healthcare system if everybody is aging, and I think most
of us will agree to that that nobody's escaping at
this moment in time. We have a huge problem because
one hundred percent there was should actually have access to
these kind of new treatments and to diagnostics, and we
are absolutely not there yet. We don't have the infrastructure

(46:24):
to do that. So I think in the end we
really should have a public health approach. Hence in Singapore
we are already working on the transition into family.

Speaker 2 (46:32):
Medicine and into GP care.

Speaker 14 (46:35):
But we really have to do and it's really dear
to my heart of having pipetted so many fiber blasts
in my life.

Speaker 2 (46:41):
We have to go from invention to real innovation.

Speaker 14 (46:44):
What really matters for the client in the moment this time,
because then we are attracting the audience and not just
with interventions which have no evidence, but how do we
actually implement the evidence based approaches in terms of gurid
diagnostics and gero therapeutics into clinical care that we are
actually making now a difference to individuals' lives. And I

(47:06):
can tell you while having many clinics.

Speaker 2 (47:08):
Yes, you can do that.

Speaker 14 (47:09):
You can lower the biological age of individuals at this
moment in time.

Speaker 2 (47:14):
What do we need? I think we need a network.

Speaker 14 (47:16):
We are needing a network not just of scientists and
healthcare professionals, which we actually did in the past decade.
We really need to have policy makers included. So hopefully
many of yours are policymakers here. We need industry partners.
When I grew up in the academic system twenty years ago,
we would never have collaborations with industry. Now in my

(47:37):
center in Singapore, we always have collaborations with industry because
we have to shape the future together because in the
end we need products for the end consumer. The consumer
is hugely important. We are writing we are signing the
first MoU now as a patient organization next week in Singapore.

Speaker 2 (47:56):
And it's not only one patient organization.

Speaker 14 (47:58):
For example of endocrinology of cancers or whatever we have,
but with the alliance of APAK and I think that's
the first step to really include the end customers in
the discussion we should have how we should shape the
future of healthcare, and not only healthcare, but I would
say of health.

Speaker 2 (48:17):
To do that, we have to publish, of course a lot.

Speaker 14 (48:20):
We need new outlets, and of course there are a
very very good journals like Nature, Aging, Lends It, Health
and Longevity, et cetera. But there was really no journal
being equipped for clinicians to write, for example, case reports
I learn every day in my clinical practice, and because
I see individuals and it's the end as one approach,
what I learned as an epidemologist and promonnymized controlled triald

(48:44):
very often does not apply to my end as one patient.
So now we have the new journal gero Medicine we
were finding with Sunsmai and diudochroma and to really also
allow these kind of really being seen, non scientific approaches
to justus explore.

Speaker 2 (49:00):
What that case really meant to shape the future of
precision gero medicine.

Speaker 14 (49:06):
And a lovely article which might be interesting for you
is the vocabulary of gero medicine. So the gyro vocabulary
where we really can understand what is how do we
defined at this moment in time which can change, of course,
but at least it's on paper, Gero diagnostiction, Gero therapeutics.
We are launching next week the ANUS Academy for Healthal Longevity,

(49:26):
the trial center.

Speaker 2 (49:27):
We're already running trials for now years.

Speaker 14 (49:29):
However we now have dedicated space, a huge trial center
with the lab, with imaging facilities, everything to the highest
standard at the NUS in Singapore. And you see that
we not only do clinical research, but we also do
clinical implementation. We have Healthy Longevity Medicine clinics aligned to
that and we have now a network that also Clinics

(49:51):
Center US their simples.

Speaker 2 (49:53):
What's very dear to mahartist education.

Speaker 14 (49:55):
How can we build an infrastructure to serve one hundred
percent of the population if nobody is trained. I always
called myself a health longevity medicine physician.

Speaker 2 (50:05):
I think I'm totally.

Speaker 14 (50:06):
Wrong and I'm not using that word anymore and also
not using positions you're a medicine physician because we even
have not defined what that is and they're really the
healths longevity medicine society kicks in because we are defining it.

Speaker 2 (50:20):
But we have to educate. We have to educate youngsters.
We are not attractive yet for the students.

Speaker 14 (50:26):
We are not in the high schools yet to really
showcase what we could do and actually showcases that they
understand why their parents are aging. So hence we have
a talent incubator in Singapore. We have intensive courses. We
all are cm are credited. We are building the master
at the moment.

Speaker 2 (50:42):
We have executive courses and the education.

Speaker 14 (50:44):
Programs in the training are running very well and we
have many educators now in the field and hopefully we
will replicate that in other countries. This is just an
example that you should have fun while creating a new specialty.
This is our healths Longevity Talent Incubator. If you have
youngsters in your companies or in your universities and your clinics,
please send them to us. Go to our website and

(51:05):
you've find how to apply for the Talent Incubator and
that incubators. We have forty most talented people around the globe.
We are selecting quite heavily. We are bringing forty to
Singapore for two weeks off a boot camp and we
did that now for a couple of years, and then
they are forming alumni classes and very often they are
now around the globe and they're forming that very very

(51:26):
strong network of having the basis of gero medicine and
gerroscience and now helping each other and really form the
next generation of talents.

Speaker 2 (51:35):
This is an important paper I would like to draw
you attention to.

Speaker 14 (51:38):
It's not published for a couple of months, where actually
we looked at the hallmarks of aging and we described
how that could actually help to bring it into the
gerromdicine arena to couple this with age related diseases.

Speaker 2 (51:52):
In this paper, from.

Speaker 14 (51:53):
Gerroscience to Gerromedicine, it's called we really describe how the
next generation or physicians should be trained and what kind
of trials we need, what kind of regulatory actions we
should actually have, and here we describe its rights the
right time not to act to bring guromedicine to fluoristion
and we are doing that since a couple of years

(52:14):
in Singapore, and this is our framework. We are really
building the framework out of guroscience. We understand the hallmarks
of aging. We have to bring guroscience markers into biomarkers
of aging that we can actually not only measure by
tophogy for example in my samples, but now also in
human samples, how do we actually measure aging except of

(52:35):
having epigenetic clocks, etc. So here the biomarkers of aging
being biological, clinical, and digital, are very important. Linking them
towards therapeutics that we can actually measure the impact of
interventions is very important. Then you see, we want to
establish many more healthy longevity medicine clinics which are in

(52:55):
a network of academic hospitals to educate and to learn
and to write the guidelines. We will then push into
the GP practices and family medicine practices, which in Singapore
is called Healthier SG. I already told you a little
bit about the Health's Longevity Medicine Society which we found
it now three and a half years ago. If a

(53:16):
bishop and myself and the first thing we said is okay,
we need a definition of what we do. Doesn't matter
if in the next year's this definition is changed. However,
now we have to have one voice being strong and
we define health and longevity medicine as optimizing health and
health spend by targeting aging processes across a lifespan, which

(53:37):
is then also very different from conventional.

Speaker 2 (53:39):
Medicine treating diseases.

Speaker 14 (53:41):
It's very different from preventative medicine, which is very often
based on.

Speaker 2 (53:45):
The layer of annual health screenings.

Speaker 14 (53:47):
So we are targeting aging process and we have to
understand how we measure it and how we antagonize it.
And very importantly is we are not excluding anybody. We
only excluding at the children because we do not yet
understand I think the biology of aging and development to
the point that we can translate that into clinical practice.

Speaker 2 (54:08):
But everybody who with age related diseases is welcome.

Speaker 14 (54:11):
You don't have to be healthy to come to healthy
Longevity medicine clinics because also the ones with age related
diseases are still still aging. If you want to learn more,
we have a conference, so we have an intensive course,
so in February it's always our week of lots of
engagement and there you will also see how the government
in industry partners are interplaying with the NUS Academy for

(54:33):
a Healthy Longevity.

Speaker 2 (54:35):
So it's education together with network forming.

Speaker 14 (54:39):
Hopefully seeing you in Singapore, I want to touch a
little bit on biomarkers of aging and then a couple
of trials. We are doing that and still being in time,
and I will only showcase you either studies which are
not yet published or which have been published recently.

Speaker 2 (55:00):
This is an important slide.

Speaker 14 (55:02):
I always show we have to match make diagnostics with therapeutics.
I think longevity clinics who just have an a la
carte menu, this is the therapeutics you can get in
our clinics are not longevity clinics.

Speaker 2 (55:17):
If a patient is coming or a person is coming
to my clinic.

Speaker 14 (55:21):
And say I want chemotherapy, I as a physician will
never give chemotherapy if that person has no cancer. And
I think it's so logic. Why should I get a
stemtho therapy without any diagnostics? And that's happening at this
moment in time the longevity field.

Speaker 2 (55:39):
So that's the reason why we are really.

Speaker 14 (55:41):
Advocating diagnose what the pace of aging is, have good biomarkers,
and then link that based on the origin of the
physiology or part of physiology to an intervention, and then
measure again and measure what the outcome is. Steve Forward
already showed you this very nice slide. I think it's
really a hallmarker paper. In cell twenty twenty three, where

(56:05):
we define what the biomarkers of aging are molecular, physiological,
and digital. We clinicians always say it's biological clinical and
digital does not matter.

Speaker 2 (56:14):
It's the same content. And here you see that we
forgot one thing, and that's actually the genome.

Speaker 14 (56:21):
We included the microbiome, epigeno and proteomics and all on
mix approaches, but we very often we're not talking about genes.
Hence we were defining a little different paper which was
published in a Nature Medicine twenty twenty four, Gerrogenes and
gerosuppressors to really guide clinicians what kind of genes to

(56:43):
measure in the field of.

Speaker 2 (56:46):
Geromedicine.

Speaker 14 (56:49):
We want to translate the biomarkers into clinical practice. And
while I am a physician working in the space, I
always ask myself what kind of claw should I apply?
And I get many emails of fellow physicians saying what
should I actually do? Which company should I use? And
I think the only proper answer to that is I

(57:13):
don't know yet. We first have to investigate that.

Speaker 2 (57:16):
Hence we were.

Speaker 14 (57:18):
Starting the Global Epigenetic Systematic Review Consortium. We have now
fifty very very talented, especially young people working in this consortium.
But we only have one question, which DNA methylation clock
is associated with?

Speaker 15 (57:34):
What?

Speaker 2 (57:35):
And the what is on the right hand side.

Speaker 14 (57:37):
Being given all the outcomes we actually measured, we have
more than thirty ongoing topics to just answer the question,
is a higher DNA methilation clock using a certain algorithm
associated with either ferilty, mortality, cancer or whatever.

Speaker 2 (57:52):
And they are doing the analysis.

Speaker 14 (57:54):
And here you'll see the first results which are now
under review, already published. DNA methalation clock associated cross sectionally
with more frility. I will showcase you it in a
second lower physical activity, higher risk of cancer, higher cardiovascular diseases,
et cetera. So now we are building that evidence base
to then also give advice to physicians or to other

(58:17):
fellow researchers. Here you see the detail and this paper
was published or accepted recently and lens it healthy longevity.
On the left hand side you see the methodology. Many many,
many papers, especially the epigenetic field is bombardingly increasing.

Speaker 2 (58:33):
It's so nice to see.

Speaker 14 (58:36):
We were finding more than one thousand, two hundred articles
primary articles.

Speaker 2 (58:41):
To be included in the systematic review.

Speaker 14 (58:43):
It's unhuman to do this. None of the students will
ever do that. So we have eye machines also helping us.
But we had to segment. Actually the association studies into
segments and therewith we have the association with the cardivascular
system with frialty, et cetera. And here I'm showcasing you
D names, inflation, clocks, associations with frialty.

Speaker 2 (59:06):
There is. So we included.

Speaker 14 (59:09):
Twelve studies, so not not really many at all yet
And on the right hand side you see the meta analysis.
And what we were able to find is that CROs sectionally,
dname methalation, clocks, the pheno he, the grimmage and the
pace of aging are associated with with frilty.

Speaker 2 (59:27):
But this is cross sectionally.

Speaker 14 (59:28):
If we are looking longitudinally, it's a little bit different. Well,
first of all, the number of studies are even smaller,
the number of individuals are not as high.

Speaker 2 (59:38):
And what we were able to.

Speaker 14 (59:39):
See that's only the GrimAge and I think ste Forward
will be very very happy with that is associated longitudinally
with the incidents of frialty, whereas the other ones are
we're either non significant or really went to the other direction.
Even so, grim age seems to be the best one.
But should I now say everybody should measure GrimAge and

(01:00:05):
of course nobody should listen to me we should from
concerts here to really build that agreement. Therefore, the Health
and Longevity Medicine Society came together with the bymarkers of
Agent Concertium and we were forming that concert team to
really write the guidelines for clinicians and advise them what
to do.

Speaker 2 (01:00:23):
You see the individuals here listed being included.

Speaker 14 (01:00:26):
Many of them are also in this room, and we
were writing the first standard if epigienetic clocks measured by
DNA mesilation should be included into clinical care.

Speaker 2 (01:00:38):
Here you see the result.

Speaker 14 (01:00:40):
So the summary of all the evidence we found in
the literature using proper techniques, and what you can see,
most associations are there with the second generation clocks. And
Steve forward already, lovely, I told you yesterday what second
generation clocks are. For example, the grimmage two is one
of them. So now we have the standard and we

(01:01:04):
have the paper is nearly ready to advise clinicians to
use at this moment in time, the second generation clocks
which are actually trained to predict mortality.

Speaker 2 (01:01:17):
But we should not forget.

Speaker 14 (01:01:18):
Other biomarkers of ag and it just show you here
Biomarkers of Female Reproductive aging, which was published.

Speaker 2 (01:01:25):
I think a week ago. We very often clinicians.

Speaker 14 (01:01:29):
Forget to look either in the mouth oral health or
think about the male or female reproductive aging. And when
we were starting all of our trials and we wanted
to look at all organ systems and physiological systems, there
were no protocols. Hence we were writing lots of papers
in the past years to actually summarize what it is.
And this is the latest consensus guideline how to measure

(01:01:51):
female reproductive aging in randomized control trials which could also
serve actually longevity clinics to implement it into clinical practice.
We also, very often we have no standards actually to
do randomized control trials and include digital biomarkers of aging. Therefore,
the biomarkers of agent Concertium was working on a standard

(01:02:16):
what actually digital biomarkers of aging up, what is the
definition of it?

Speaker 2 (01:02:19):
And you see it on the left hand side.

Speaker 14 (01:02:21):
But also very importantly what is already used in clinical
trials and not in the longevity space, but really in
the cardiovascular, endocrine, et cetera space, what we could actually
borrow and use for our trials. And you see that
summarized on the right hand side. So I think the
time is really right, not only to use it in
clinical practice. All my patients have actually digital device and

(01:02:44):
we can track them real time that my healthcare coaches
can actually tell patients what to do or not to
do or nutch them into certain directions. But we should
absolutely not forget to use these digital biomarkers in our trials.
And that brings me to my last section. These are
the trials which are ongoing. We are recruiting at this
moment in time at the ENUS Academy, and one of

(01:03:05):
them already finishes the Able study where we are giving
alpha quito glutererate to forty to sixty year olds which
are healthy, but we also investing in multi vitamin minerals.
We are doing multimodal interventions now where we are combining
lifestyle interventions together with nutaceuticals and even drugs like GLP
one receptor agonist or s GILT two inhibitors. And we

(01:03:27):
also look at how can we match make it to
the gyrodiagnostics who should we actually include. And we have
a consumer survey model which is a halo study, and
the clinical models that's the Hell study where we already
implemented it into clinical into clinical care. Just a snapshot
about alpha quito gluterate. It's a very powerful molecular could

(01:03:49):
be a powerful molecule to actually reshape our epigenetic makeup
and out mitochondrial function and therewith could influence many.

Speaker 2 (01:03:57):
Of these organs which are depicted here.

Speaker 14 (01:04:01):
When we were starting the ABLE study, we said, okay,
we want middle aged individuals, which is our prime target
and our trials. And we said, okay, should we include
everybody or could we actually enrich the chance that we
would see something a positive result if we would only
include the ones who are healthy but they are biological older.

(01:04:21):
So there was having a propensity of a risk of
an age related disease later in life and later in
life most of the times it's in the next coming
years when you're forty to sixty and hence we were
the first only including individuals with a biologically older measured
by four different epigenetic clocks individuals compared to that chronological age.

(01:04:46):
So in the ABLE study, we only included forty to
sixty olds with no chronic diseases but being biologically older
measured by DNM DNA methylation compared to the chronological age.

Speaker 2 (01:04:58):
And we did that because we started three years ago.

Speaker 14 (01:05:01):
Now did that based on two first generation clocks and
two second generation clocks, which is also our outcome. Yeah,
you see the EKOG design sixty sixty individuals plus ebo
versus a gram of alvaqito gluterate. Lots of outcome parameters,
and the primary one was the medium of four epigenetic clocks.

Speaker 2 (01:05:25):
Recruitment is going very well.

Speaker 14 (01:05:26):
I got the criticism in the beginning, you will never
be able to find biologically older healthy individuals being forty
to sixty.

Speaker 2 (01:05:33):
I said, why, like fifty percent should be older.

Speaker 14 (01:05:37):
At least, and I would say, and hopefully not everybody
has EH related diseases. But you can see within a
year time we had the recruitment and everybody was happy
being in this study. You see here a little bit
more of the detail of recruitment to first have to
screen the ones being in the trial design phase.

Speaker 2 (01:05:58):
Here it's really real, relatively.

Speaker 14 (01:06:00):
Easy to find these individuals forty to sixty because these
are also the ones who want to come to longevity clinics.
So in the end, roughly we included from screening to
inclusion twenty five percent of the individuals, and I think
that's quite good. I did other studies in my life,
where it could was only able to include one percent
or ten percent of the of the individuals. You also

(01:06:25):
see that the randomization quint went quite well al faquita
mutererate versus placebo, all the measures are the same between
the groups, and very importantly the media and DNA H
is higher of course compared to their chronological age being
fifty and there were roughly biologically forty fifty four to

(01:06:45):
fifty five.

Speaker 2 (01:06:47):
Not many adverse events, no dropouts.

Speaker 14 (01:06:50):
So also here showcasing that I think we have a
highly motivated group of biologically all the individuals who really
want to make this with work. And if there are events,
it's the same in both groups. Very good adherents more
than ninety three percent had pill adherents of at least

(01:07:10):
eighty percent, which is the characteristic in the trials, which
means that it went well and it's the same in
the placebo versus the control erm.

Speaker 2 (01:07:19):
Who you see the main result it worked a little bit.

Speaker 14 (01:07:25):
So we took individuals and they took six months of
one gram of alphacito groutarate and we did the responder analysis,
and what you can see in the upper panel is
that we had many many more responders in the AKG
group compared to the placebo group defined as at least
one and a half years of biological AH reduction, using

(01:07:47):
again the same markers. While being in the AKG group,
it really worked well in individuals who were already weller,
who had at least, for example, six thousand steps a day.
So here we see really that finding the right individuals
of the right needs for the right intervention is of
utmost importance. Unfortunately, all our secondary outcome parameters.

Speaker 2 (01:08:15):
Are not different between the groups.

Speaker 14 (01:08:17):
So if we are looking at cognition, or we are
looking at massive strings or massle mass or endurance, we
measured all the organ systems. There were no significant differences. However,
biologically on molecular level we see it, but not on
clinical level, which means either we have to give higher
dosages or we have to treat individuals for longer. So

(01:08:39):
requipment is feasible limited adverse events. It works on biological
level and secondary outcomes are not there.

Speaker 2 (01:08:49):
The last thing we have to mix up our.

Speaker 14 (01:08:52):
Interventions and do multimodal interventions. If you are looking at
conventional medicine, very often we don't do that. IMGORI autrition
Hence all my patients have many, many, many many drugs,
and all the drug drug interventions and possible interactions have
never been studied.

Speaker 2 (01:09:11):
I think we have to be smarter and better.

Speaker 14 (01:09:14):
And the first time that we are doing that in
our group is in our ex Prize study Prometheus, where
we are including following the X Prize alignment fifty to
eighty year old which can have h related diseases. And
what we have chosen we are doing a foundational intervention
looking at sleep dietary intervention. SOI protein, we are given creating,

(01:09:37):
we are giving for coidon, and we're giving exercise with
exa gaming next to that, and then based on the
age of type of individuals, we are adding either drugs
you're seeing them on the right inside or and nutraceuticals
other nutriceuticals like an amen and for coid and et cetera.
And the primary outcomes is being given by the X Price.

(01:09:58):
And here you see how it looks like. The study
is only two months, so we are screening individuals, we
are doing the assessments and based on the age of type,
we are giving the ratios and the type of drugs,
the type of nudoceuticals and all get the lifestyle interventions
and then after four weeks we are measuring again and
based on the age of type in if they increased

(01:10:20):
or not increased. We are adapting as you would normally
do in clinical practice our regime, and that could end
up with people having an amen, having your listena, having
a GLP one receptor agonist, et cetera. Everything is scripted,
which means there's none of the decisions we are going
to major is unscripted. So hence we can also then

(01:10:41):
transfer that into clinical practice into guidelines. We are recruiting
and we are doing the intervention at the moment, and
in December everybody is out and in January we will
have the results. So guroscience great. I think we are
there to translate. We have to define eurodiagnostics, therapeutics, and
I think we are ready to really shake up the

(01:11:02):
healthcare system to implement precisions your medicine.

Speaker 2 (01:11:05):
Thank you, thank you, the lovely Lady in blue. Can
we put on the mic please? Thank you Andrea very
much for that great commentation.

Speaker 16 (01:11:25):
I just want to know you work on that pavior
on favor for the jour yes, and I want to
know in that person time ever you mentioned aging as.

Speaker 14 (01:11:39):
A disease for the other member to make sure that they.

Speaker 2 (01:11:43):
Homs actually, and I really want to know, how what
do you think black out a chance?

Speaker 15 (01:11:53):
In Singapore, everybody is aware of what you are doing
and you get a lot of funding and a lot
of support. But unfortunate I don't see that in Germany
and I don't see that in Europe. So what do
you think how long does it take that they understand
as well that this is necessary what you were doing.

Speaker 5 (01:12:08):
So I have super positive for.

Speaker 14 (01:12:13):
The Leopoltina brought us together and we wrote that manuscript
document within two months, and there's lots of attention with
the media.

Speaker 2 (01:12:22):
I was recently in Hallo like three weeks ago and
two deans of medical schools approached me. And this is
in Berlin and that's in Halle. We won't tell the
longevity medicine clinics.

Speaker 14 (01:12:33):
So they are now right now implementing it not only
into the curriculum, but also they already have space to
implement it.

Speaker 2 (01:12:41):
So it's hugely changing.

Speaker 14 (01:12:43):
I'm with government at the moment in Germany, I think
do to my origin having a German.

Speaker 2 (01:12:47):
Passport, and are hugely focusing on it.

Speaker 14 (01:12:50):
So Germany I would say compared to other countries, is
absolutely at the forefront in Europe.

Speaker 2 (01:12:56):
So no, it sums up, got it?

Speaker 4 (01:13:01):
Germany is at the forefront of Europe. Any more questions?
Seize the momentum? Did Steve Stephen?

Speaker 2 (01:13:08):
Yeah? Did we have a mic? We have a loud voice.
You're close to us.

Speaker 6 (01:13:13):
Yeah.

Speaker 11 (01:13:13):
I think your efforts for promoting therein medisine a little reparkable.

Speaker 10 (01:13:19):
I really love the work of the human limited pric
as opposed to mine.

Speaker 9 (01:13:25):
I think your comment on when do we find out
what the results about to koidan supplementation?

Speaker 14 (01:13:33):
Okay, so the question is when do we hear about
for Coyden. So for Coyden round seaweed is in our oceans,
and we know that Japanese people live longer. Hence we
think is their SIXX activator might actually help for humans
we are recruiting at this moment in time, we have
the first participants in there. We are only doing that

(01:13:53):
in fifty to eighty year old males, being pretty free
because we know from studies my set especially it worked
in pre thrill.

Speaker 2 (01:14:03):
Mice compared to younger mice. So we are translating that
the moment in six months time, you will have the results.

Speaker 4 (01:14:12):
Thank you so much. Please give it up for Andrea Meyer.
So hopefully you're feeling energized. Your minds are open, your
hearts are open, and you're really energized for this next session.
And with that, it's time to hand over to our

(01:14:32):
third speaker of this session, who is investor and founder
of Human Longevity and Rejuvenation Syndication and also strong advocate
for longevity benefits.

Speaker 2 (01:14:41):
Please give it up for Ken Scotts.

Speaker 9 (01:14:52):
Okay, So, Jose and this organization are very much into immortality,
and I'm going to talk this morning about therapies that
I think will help us achieve that immortality. I think
of it as a road, a road that stretches way
out there to the horizon, and we're all on that road,

(01:15:13):
and that road starts with our birth or perhaps if
you prefer our conception. And where's the next stop, the
next sign post on that road? I suggest it's probably
out there eighty years. That's sort of our expectant life expectancy.
And so I ask you a question. And I can't
see the audience, but I wonder how many here have

(01:15:37):
completed eighty turns around the sun. Can I get a
show of hans. Can somebody tell me how many?

Speaker 10 (01:15:43):
Is it?

Speaker 12 (01:15:43):
Just?

Speaker 9 (01:15:43):
Helga? Helga? And perhaps only four percent of the population
or two percent of the population. In the United States,
it's the same in most developed countries. Is over the
age of eighty, only about one percent of the population
can actually look after themselves. Seventy five percent of the
people have a need for care. What's the next stop? Well,

(01:16:06):
let's not go another eighty, Let's go another twenty. Where
are we at one hundred? Turns out that at one
hundred years, we only have about point zero three percent
of our population alive. That's three people in ten thousand.
Oh what about the next twenty years? One hundred and twenty? Whoops?
Nobody there. That's the problem that we have with immortality.

(01:16:31):
So what I'm going to do this morning is talk
to you about some of the things that we can
do to achieve the rejuvenation, which is really the only
solution to immortality. And we've had a couple of speakers
already talk to us about Yamanaka and the Yamanaka factors
and the proof that we can take old selves and
make them young and the challenges to do that for

(01:16:52):
a whole body. But until we can do that, what
do we do? So I'm going to talk to you
about some of the therapies that I have taken, which
I think are very effective, and there's sort of in
three areas of intervention. First of all, I'm going to
talk about peptides, and I'm going to mention first of
all that peptides are very small proteins. I think you
probably all know that, less than fifty amino acids. And

(01:17:14):
the three that I'm going to talk about are the
cabins and peptides, some peptides that come from one skin
OsO one and also some fairly new peptides BCP one
five seven and TD five hundred. The cabins and peptides
I've been taking for about five years. I take two
capsules a day, for ten days of the month, I

(01:17:35):
take five different ones. You can see on the chart
pay perhaps that there's a mixture of about twenty one.
We vary those typically from month to months, and you
can see some of the results there. Yesterday Maria Glasco
was talking about telemar length and you can see the
effect of these therapies on my telomere length, which has improved.
We had talks by Andrea A. Few minutes ago about

(01:17:59):
biological age. You can see some evidence that I had
some biological age improvement. It works one skin's peptide. One
skin has a peptide for the skin. I should have
mentioned that the cabinsin peptides will come if you take
them with a warning that they're not suitable for human consumption.

(01:18:21):
They're for animal experiments only. I don't know why we
pick on animals. I take them one skin has a
peptide that they put into a skin cream, and cosmetics
are not controlled by governments the way internal consumption is took.
I was involved in the original trial of this product

(01:18:44):
about four or five years ago. I've been using it
ever since. And this is a little picture from the
first I think ninety or one hundred and twenty days,
and you can see the effect of that one skin
peptide on my skin. You can see the effect around
the eye where it removed the age marks, and you

(01:19:05):
can see the effect around the mouth where it significantly
reduced the wrinkling and so on. I won't talk about
the blast peptide, the BCP one hundred or one five
seven and the five hundred. We're still working on those.
It's a work in progress at the moment, but it
has had amazing impact on the condition of my wife

(01:19:28):
who suffers from dementia. Going on, we talk about the
fallostatin gene therapy that comes from Mini Circle. This is
a plasmid. It's about basically encoded with the gene for fallostatin.
It's injected into the abdomen or into the muscles. Got

(01:19:50):
a problem here.

Speaker 10 (01:19:51):
Let me see.

Speaker 9 (01:19:54):
What it does, of course, is it produces follostatin. It's
a serum based fallostatin. It gets into the muscles and
it has some very interesting potential. It will strengthen your
muscles and it will also improve bones density. And so yeah, okay,
so it's in the blood, as I say, And here

(01:20:16):
are some results. And I don't know how visible those
grafts are there. Not bad, okay, So first of all,
you can see some bone density. It's sort of floating around,
but at least mostly.

Speaker 5 (01:20:26):
It isn't decreasing.

Speaker 9 (01:20:27):
But you'll notice that after two years, just sort of
back to baseline, there's an increase in the fat pree mass,
muscle mass. I weigh about fifty five kilograms, and my
lean muscle mass increased by two kilograms and that increase
has stayed, although other aspects of the therapy sort of decreased.

(01:20:49):
After two years. You can see here more dramatically on
the left the increase in the polostat in three four
four levels sword over the first year, but after two
years we're back down to baseline. And I actually had
another injection of the fallostatin therapy about two months ago.

(01:21:11):
In another month, we'll see how the blood serum FST
level is. And then on the right you can see
how the epigenetic age decreased. And Andrea might find this
interesting because I went from I think seventy one to
eighteen for a little bit of time, and that's I
think a world record in decreasing biological age. The next

(01:21:38):
therapy I want to talk to you about is what
we call v cells, very small embryonic like stem cells,
and these are taken from the blood and the procedure
is to take about eighty c c's of blood, spin
it down to get the PRP. I radiate the PRP

(01:22:00):
with lights of a certain frequency to activate the stem
cells that are in the PRP. And these are stem
cells that we all have in our blood all our lives,
but they become inactive during the embryonic stage of development,
and they can be reactivated by this light. And so

(01:22:20):
then what we do is we reinject this activated PRP,
typically intravenously as a systemic treatment. I also have had
it on my injected into my knee. In addition, and
one of the other things that we've done is we
take some of these stem cells and we nebulize them

(01:22:42):
and we actually inhale them into our lungs so that
we're getting those stem cells going right into the pulmonary system.
And here are some images associated with that kind of treatment.
The first one you can see that I am standing
there with a light being directed at my body. The
light that you can see is not the active light,

(01:23:03):
it's a targeting light. But essentially what's happening here is
we're trying to attract the stem cells into a particular
part of the body. And one of the treatments that
I had about a year ago was really impressive. I
had an injury to my right knee from jogging on
a sandy beach forty five years ago, and like some

(01:23:24):
of those injuries, over time, it was getting worse. It
was really bothering me, and so we did this treatment
that we targeted my knee, and four days later it
was back to normal and I have no knee problems
now a year later. In the middle photo, you can
see me breathing the nebulized B cells, and then on

(01:23:47):
the right you can see that the B cells are
being injected by a needle. One of the things that's
happened to me over the last few years is I've
become rather vain. I like to have facials occasionally. I
got new teeth, happy to smile, you know, look good,
feel good, feel young. And so that's what we're doing.
On the right hand side, I've had a couple of
those facials. But what's on the horizon. I'm telling you

(01:24:13):
about things I've done. Oh, by the way, I should
say that all of these treatments I'm doing simultaneously, which
relates back to what Aubrey was talking about earlier today,
where he was talking about simultaneous tests with mice and
how sad it was that we didn't do those kinds
of tests. Well, I do it as a human and
there are quite a number of my friends who are

(01:24:34):
doing the same thing as we go. Well, guess the
other thing I should say is the foalostatin has not
approved anywhere, but you can get it in Panama the
clinic that I'm involved with. I actually got it the
first time in Prospera in Honduras, and the b cells
you can get in some places, but it's very important

(01:24:57):
that any doctor who gives them not play any resis.
Alts are possible. So what do we have coming up? Well,
first of all, we bought some and this is important
for older people. We need to be concerned about our eyes.
And there are a couple of treatments that are either
available or coming soon. Lento Bio have an eye drop
which will increase the elasticity of the lens.

Speaker 6 (01:25:20):
Which will we hope.

Speaker 9 (01:25:22):
All of our tests so far indicate the elasticity will
improve and will stay so that you would probably take
this for maybe three months or so and then do
that every two or three years. Also, you can use
algebrium to counteract the effect of cataracts. My wife has

(01:25:42):
done that quite successfully. In the dental area. The Japanese
are doing some really important stuff. They're actually regenerating teeth
from stem cell treatments in the mouth, and you know,
we've got to get rid of this dentistry stuff. Pathos
Girls's cyclarity is doing human trials clinical trials at the

(01:26:05):
moment in Australia and Repair Biotechnology who have a enzyme
that will catabolize after squatic plaque probably will do those
tests in the next three to six months. I will
be one of the first recipients.

Speaker 2 (01:26:22):
We've got a new.

Speaker 9 (01:26:25):
Mix and gene therapy coming out from Triple Helix. It
will be a combination of polystatin, CLOTHO and certain one.
It will be delivered by an AAV vector. I will
probably get that as Helga will sometime in the next
three months. This will be because it's an AAV vector,

(01:26:46):
we would expect the results to last several years. The
other thing that's coming up which is really exciting and
where there was a comment on this yesterday, I believe
and this relates to mitochondrial replacement, the idea of taking
young mitochondria and creating a batch of them using bio
reactors and then turning that and injecting into the body

(01:27:07):
to replace the aging mitochondria. Both Helga and I have
had are mitochondrial DNA damage levels measured, which is quite interesting.
And then of course we have the transfection of the
OSK factors, and this is being worked on by Age
Reversal Network under Bill Fluon. So these are things that

(01:27:29):
are coming. What are my conclusions from all this, Well,
first of all, although the mitochondrial and the osk transfaction
are out there and hopefully coming, and maybe it will
start happening in the next year or two, I need
to do things in the meantime. I need to provide

(01:27:50):
nutrition to my body. And I believe that my body
knows how to use the transitions or the impact of
the nutritions that we give it through systemic injects. I
really believe that the mind knows how to handle the
allocation of those resources, and so I believe that my
body is actually being rejuvenated gradually. And you can judge

(01:28:13):
for yourself, of course, and I want to show you how.
I apologize that there's no sound. This is Bill Haley
and the commets back from the nineteen fifty two era
when I was a teenager. But you can see that's Helga.
In the previous one. It was Helga and I dancing,

(01:28:35):
and you can see that I do a lot of
other interventions at the same time. Now I think, and
I go back to Obray's comments, if you have a
minutes earlier where he was saying that you're interested not
only in numbers, but you're interested in how does the
specimen look and how does the specimen act? And I

(01:28:56):
believe this demonstrates that I am impact rejuvenating and that
rejuvenation presumably qualifies me for the exprize. And going on
from that, you might say, well, who is this crazy
old guy who does all these therapies that are not
approved by this, that or the other government, and who
goes anywhere to do it? So let me just tell

(01:29:16):
you a little bit about myself. So in the longevity field,
we've seen in recent years quite a massive increase in
the number of longevity experts. Okay, And so i don't
have a PhD in bio. I'm a mathematician by training. Ah,

(01:29:40):
I'm not an MD. I've done a few things in
my life. In recent years, I've been focused more on
the biotech field. As I said, I was in the
bun Skin test. I present at conferences, I'm being a

(01:30:03):
test subject for Mini Circle. I'm an investor in startup
companies in the biotech space. I'm an advisor. I'm a biohacker.
So I claim to be a longevity expert, and the
qualification that I offer you is my birth here and
if you've got experts talking to you who are half
my age, don't take it too seriously. Now, if any

(01:30:26):
of this interests you, I am writing a book and
you can go there and register. I'm hoping it will
come out sometime in the next two or three months.
And I think that's I tried to talk as quickly
as one Carlos. I knew I couldn't present this in
Spanish at anywhere near that speed, and I was told
I had to be very careful about not exceeding my

(01:30:47):
fifteen minutes.

Speaker 16 (01:30:48):
So there we are.

Speaker 5 (01:30:58):
Yes, thank you so.

Speaker 4 (01:31:00):
Much to Kelled and thank you also for you know,
being an advocate for human trials, as I e yourself,
because it's always interesting to sort of see over correlation
of longer time. But you're also doing certain therapies that
aren't even FDA approve, which.

Speaker 9 (01:31:16):
I would say that human trials are incredibly important, but
I also am concerned about agism. One of the problems
we have with the few human type activities that go
on now is that you know, Exandrea was talking about
some of the stuff they're doing. It's on people who
are forty to sixty years old, you know, it's agism.
Those of us who are over eighty need a little

(01:31:37):
more attention.

Speaker 2 (01:31:39):
Very true, because.

Speaker 4 (01:31:42):
Thank you being an aging demographic, Being an aging demographic
in the world, I.

Speaker 2 (01:31:48):
Think it's very important.

Speaker 8 (01:31:49):
Okay, we are very lucky in Spain because we have
had a previous week of another fantastic activity called Longevity
Biotech Fellowship.

Speaker 6 (01:32:00):
And during that.

Speaker 8 (01:32:03):
Week there were about one hundred people from all over
the world who are interested in longevity and how to
do something now, and there were fantastic speakers and advisors.
And one of them is a very young guy, which
I admire because he's so young and energetic, and he
will be tonight at the Madrid Longevity Right Party. I

(01:32:27):
actually know his father also, But Dylan is the new generation,
and Dylan Livingstone, who lives now in the Washington area,
he's doing the best lobby ever in the planet. He's
lobbying for the government of the USA to open up

(01:32:48):
its mind and to begin looking into longevity as an
opportunity for investments, for growth and for health, because I
like to say he health is wealth and so with that,
I truly want to invite Dylan Livingstone to present about
his incredible advancements in science.

Speaker 17 (01:33:16):
Well, first I'd like to say thank you to Jose
and the Transvision Madrid community for allowing me to speak,
and for putting on such a wonderful conference in such
a beautiful hall. This is you know, we don't we
don't get this in DC. We get a lot of
corporate buildings. So this is a fresh a breath of
fresh air. So I will tell you a little bit

(01:33:36):
about my personal journey into longevity. I'll tell you a
little bit about the work that the Alliance for Longevity
Initiatives does, and then kind of go into the economics
of longevity and why this really is the opportunity of
a lifetime for investors, for governments, for the general population,
because as Jose said, health equals wealth. Right, So a

(01:33:58):
little bit about me.

Speaker 6 (01:33:59):
So who are we?

Speaker 17 (01:34:00):
A f l I. We are a five oh one
c four nonprofit organization based in the United States focused
on representing the longevity, biotech and overall longevity communities interests
with legislators, with government officials, agencies, et cetera. We were
established in twenty twenty two. It's I can't believe it's

(01:34:21):
already been three years. Time is flying. We got to
work on this longevity stuff because it's going too fast.
Our mission is to advance legislation that extends healthy lifespan
on Capitol Hill via advancements in longevity biotech, via advancements
in sensible solutions to medicare and health insurance, and you know,

(01:34:45):
the entire kit and kaboodle. But you know, my personal
interest here came is in longevity biotechs. So that's where
we do a lot of our work, and that's where
we focus. I want to give you my story of
how I got into this field because, as Jose said,
you know, I'm a pretty young guy. I'm twenty seven.
You know, when you're in your mid twenties, you don't
really I guess I am in my late twenties or

(01:35:07):
mid twenties at twenty seven, I'm not really sure. But
in your twenties you don't really think about longevity too much.
And when I talk to my friends from college and
high school, you know, they kind of look confused when
I talk about my interest in the longevity space. So
I'm going to tell you my background and I think
that's a very important thing to convey for all of you,
to convey to people you talk to about this space.

(01:35:28):
I got interested in the longevity space when I was
about thirteen years old. My father, who Jose also knows,
is an investor in next generation technologies, and he was
driving me to school one day and he pulled up
a video and he said, look at this guy I
met at this conference. This guy is outstanding. I think

(01:35:48):
he might know who this guy is. He's got a
very long beard. I think he spoke earlier today, kind
of looks like a wizard. His name is Aubrey de Gray,
and he was talking about the Quest to Defeat h
And as a thirteen year old you kind of look
at him and you say, Wow, what's this guy up to?
I want to know more about what he's thinking about.
But you don't really think about aging at thirteen years old, right,

(01:36:10):
It's more of like this distant thing. You don't really
have the cognitive abilities to even comprehend what it means
to age. Fast forward a couple of years. I kind
of buried that whole world in my mind, and then
COVID hit, and I think the ravages of aging were
very apparent to all of us. I'm sure everybody in
this room probably had someone that they knew that were
afflicted by COVID, probably of an advanced age, And that

(01:36:33):
kind of changed my thinking about life. It changed the
way I looked at the future. It changed the way
I looked at politics and health and life in general.
And I remember being locked in my parents' basements and
really kind of depressed about the prospects of getting older.
And I realized that I knew about this guy who

(01:36:54):
my father showed me when I was thirteen doing something
about it. He was trying to advance the cause to
stop and eventually cure aging, and that really inspired me
to take action. At the same time, I was working
in politics. I was working for the Democratic National Committee,
and I eventually went on to work for Joe Biden's
campaign in Pennsylvania. And what I realized after listening to

(01:37:16):
a number of the influential speakers in the space talk
and reading books and et cetera, was that there was
no voice for this community on Capitol Hill, and there
were a number of things that needed to change if
we wanted to see real progress in this space. And
so I don't know if this was bravery or complete delusion,
but at the right page of twenty three years old,
I decided to take on this mission myself and create

(01:37:39):
the voice for the longevity industry in DC. So that's
my backstory, and I encourage all of you when you
talk to people that are not you know fully west
gen z Er say longevity pilled when you when you
haven't taken the who's seen the matrix? I'm sure some
of you seen the matrix. For people that haven't taken
the longevity pill. I think it's important to lead with

(01:38:00):
your backstory because this is a very personal issue for
all of us, and you know, at the end of
the day, we're doing this not only for ourselves but
for the people that we love, and we want to
convey that to as many people as possible because this
is the ultimate, the greatest humanitarian mission of all time,
the Alliance for Lunch. So that that's my backstory. After
I made this realization, I went on to create the

(01:38:21):
Alliance for Longevity Initiatives. We've been around, as you can
see for about three years now. I'll kind of I
have another slide about this, but I'll kind of go
into it now and kind of talk about some of
the things that we've done over the last three years.
The first thing we did as an organization is we
established a Congressional Caucus and the House of Representatives, so
a special interest group in the House of Representatives to

(01:38:44):
advocate on behalf of the longevity industry. And so I'm
very proud to say I like to pat myself on
the back for this. It's a bipartisan group of lawmakers.
You know, you go to Washington, you tell me what
other things are bipartisan? You know, nothing, right, but the
quest to live healthar and longer is one that brings
people together and that's very touching and encouraging to see.

(01:39:08):
We also passed a series of laws in Montana. So
I don't know how many of you are familiar with
that small state in the middle of the country in
the US, but Montana that expands eligibility under the Right
to Try Act. So Right to Try was a law
that was passed in twenty seventeen by the Trump administration
that allows patients with terminal illnesses to try therapeutics that

(01:39:29):
haven't been fully approved by FDA.

Speaker 6 (01:39:33):
That is a great law.

Speaker 17 (01:39:34):
It's a no brainer right if you are on your deathbed,
you obviously should be able to try and exhaust every
option and avenue to make yourself healthy again. But that
doesn't fully jive in my mind with the longevity industries
and communities mission here. Right, we want to be preventive
and proactive with our health. And so what the laws
that we passed do are open up eligibility under this

(01:39:54):
right to try law to healthy patients as well. And
so now if you're a healthy patient and you want
to go try the latest analytic or mitochondrial dysfunction drug,
et cetera, you can go to Montana and you actually
have access now, and that's very exciting. I came at this,
you know, from looking at people traveling abroad to places
in Central America and Eastern Europe, and I saw that

(01:40:15):
people were going abroad to get these experimental treatments, and
I figured, you know, why not do this in America.
We're losing out on economic opportunity, data collection, et cetera.
And so I think kind of centralizing that in the
US is a very beneficial thing for the field, and
we can accelerate the developments of longevity medicine in a
major way by having Montana as this state so now

(01:40:38):
I'm actually going to get into my talk. That was
all like the intro stuff. Now let me get into
the talk. So the economics of longevity. Why is this
the greatest opportunity, the greatest problem, and the greatest opportunity
in the history of humanity? So the first thing is
there you go, the world is getting older and sicker.
I think all of you probably know this. You look around.

(01:40:58):
I've been in Madrid for a couple days now. I've
seen far more people above the age of sixty five
than i've seen under the age of eighteen. I would
say it's very obvious just by looking around. But the
statistics show that our world is getting older and sicker
as well, right, people are You're not supposed to be
able to read all of this, by the way, I
don't even try. But what I want to really convey

(01:41:19):
to you on this chart is even in the healthiest countries.
So we all think of Japan and Switzerland and Australia
as being very healthy countries, even in these places people
live about twelve percent of their lives in really poor,
disabilitating health. If you look at my home country, the US,
where I'm a little embarrassed about that we have the
longest six span in the entire developed world and the

(01:41:41):
shortest health span in the entire world. So I'm obviously
trying to fix that. But you know, these numbers actually
have implications for how society runs.

Speaker 6 (01:41:52):
In America.

Speaker 17 (01:41:52):
I can speak specifically about America, but in America, you know,
we have a growing deficit problem. And that's really driven
not by you know, expended by the government to USA
I d. It's really driven by the fact that Medicare
is continuously being sucked up by our elderly population, and
that's going to continue to grow unless something changes. The
thing that will that can change this, this Medicare product

(01:42:15):
projection right here is the advent of longevity medicine. And
so that's why I'm so passionate about developing and and
and putting money towards developing these therapeutics and these drugs
for our older population and our younger population. If we
nip this in the bud, now, then you know, these numbers,
the one point eight trillion dollars will be curbed, and
you know, Elon Musk won't have to take a chainsaw

(01:42:37):
to to all the UH, to all the government programs.
The issue though in the United States. And this is
actually the United States is actually sort of leading the way,
but not leading the way enough in the developments of
longevity biotech. The issue is America doesn't really spend enough
money on the biology of aging. So we have a

(01:42:59):
budget in the NIH with the NIH for of about
forty billion dollars a year. The Division of Aging Biology
gets less than four hundred million dollars a year, so
less than one percent of its budget goes towards this
issue that drives ninety percent of disease and death in America.
It's a complete misallocation of funding. And that's part of
the work that A four LI does is explaining this

(01:43:21):
to appropriations committees, to energy and commerce committees, et cetera,
that this is a problem that needs to be focused
on and fixed. So opportunities. So, how many of you
here have heard about the longevity dividend? Raise your hand?

Speaker 6 (01:43:35):
Not that many?

Speaker 17 (01:43:36):
Are you just being shy or okay, I don't know,
but the longevity dividend. If you're in the longevity field,
this is something that you should be very aware of
because this is, in my opinion, the most compelling economic
argument for the longevity industry. There have been a number
of studies over the past couple of years showing what
the implications would be if we extended healthy life span
in our population and what would that mean for our

(01:43:58):
economic value. There's another, Like I said, there's a number
of them. They don't show exactly what I'm showing you here,
but this is my favorite economic analysis of the longevity dividend.
This was done by Andrew Scott and David Sinclair, who
I'm sure all of you know, and it showed that
even one year of healthy life extension in a population
would equal thirty six, well thirty six thirty seven trillion
dollars of GDP gains. Thirty seven trillion dollars is about

(01:44:23):
one hundred and five hundred and ten percent of what
the US economy is right now. And you know that's
just for one year, right, so if you kind of
scale it up, they show that over you know, if
we can increase the average healthy life expectancy by ten years,
then we gained to we gained potentially several hundreds of
trillions of dollars in GDP gains. And where does that

(01:44:44):
come from? Obviously it comes from you know, people being
more productive. Right, If you are not sick, then you
can contribute to society in a more meaningful way. You
can work, you're economically productive, but then you're also contributing
to society by going out and spending money, and and
you know, increasing GDP gains that way. On the on
the flip side, I was talking before about medicare, We're

(01:45:06):
not spending as much if people are healthy on keeping
people alive in a six state right, So this is
where the economic analysis comes from, and it's very compelling,
especially when I go talk to politicians. This is the
thing that they care about the most. You know, they
like the moral aspect of it. I like the we
all want to live healthier, longer, but they care about
getting re elected. They care about, you know, showing that

(01:45:29):
their specific constituent district is doing a good job and
job opportunities, et cetera. And so this is the thing
that really resonates the most with politicians. And if you
ever speak to a politician, I highly recommend bringing up
the longevity dividend. And so this is another slide here,
but I basically just said all this, so I guess
I can skip. So that our solution to getting the

(01:45:53):
longevity dividend implemented in America and the world is by lobbying. Right,
the government has a lot of levers at its disposal
that it can pull to ultimately yield the longevity dividend
for its population. So right here you'll see, you know,
I gave some back of the back of the napkin
math here on what other industries spend on their lobbying

(01:46:15):
efforts and the returns that they get. So the Alzheimer's Association,
which is the major Alzheimer's industry association in DC, they
put about four million dollars into lobbying back in twenty
twenty four. Twenty twenty four, mind you, was a continuing
resolution year, which means that there was really no changes
in the in the budget bill, but they still ended
up getting one hundred million dollar increase in Alzheimer's research.

(01:46:38):
That's a twenty five x ROI. Right, if you put
you know, money into the stock market, you got a
twenty five XROI, you'd be pretty happy. Military contractors are
even you know, greater than that. They spend about one
hundred and forty five million dollars on lobbying, and each
year the Pentagon shells out four hundred and thirty one
billion dollars in contracts for the military industry. Right, And

(01:47:00):
so you see obviously in yellow, I wanted to highlight
this point. The more we put in, the more we
are going to get out of the government. But we
need support, We need engagement from all of you in
America and beyond to really get the most out of
our governments for this issue. I mentioned we did a
bill in Montana earlier this year SB five thirty five,

(01:47:23):
and I kind of wanted to give that as a guide.
So we spent about sixty thousand dollars on getting this
bill passed through lobbyists, through advocacy materials, et cetera. And
you obviously can see at the bottom of Montana is
a population of one point one million people. You scaled
it up to the US's population, and then he scaled
up the amount we spent in Montana. If we spent

(01:47:44):
twenty million dollars as an industry on lobbying, we would
get the same return of value from the federal government.

Speaker 10 (01:47:50):
Right.

Speaker 17 (01:47:51):
So again very back of the Napkin math here. You know,
I'm not a mathematician, I'm a politics guy. So don't
you know, don't I'm sure there's mathematicians out here.

Speaker 6 (01:47:58):
Don't don't.

Speaker 17 (01:47:59):
Don't roast me, all right, but this is the kind
of framework that I'm thinking about. And if we can
put substantial money into this, but not too substantial.

Speaker 6 (01:48:05):
We don't need.

Speaker 17 (01:48:06):
Twenty million dollars is a reasonable series A raise for
one biotech company. If we can put this into lobbying,
these are the.

Speaker 6 (01:48:13):
Kind of returns that we get.

Speaker 17 (01:48:15):
So I spoke a little bit about our accomplishments. I
think I messed up, and I put this lad at
the end. I'm sorry about that. But you'll see me
here at our DC summit last year with doctor Oz
who's the director of the Center for Medicaid Services, with
doctor Mike Roysen from the Cleveland Clinic, and then on
my left is Congressman Gus bill Arakis, who's our Republican
co chair for our Longevity Science Caucus, and Congressman Paul

(01:48:37):
Tonko who's the Democratic co chair. So my ask to
all of you is two things. One, get involved right.
Your voice matters when you're talking to politicians. This is
the ultimate issue. This is the ultimate humanitarian issue that
the entire world needs to take. You focus on Otherwise
we're screwed. We're just genuinely screwed. Our social systems are comic.

(01:49:00):
Productivity is going to collapse because we're gonna have too
many old people that are reliance on the system. Right,
So this is the ultimate humanitarian issue from a moral standpoint,
but also the ultimate economic issue that we need to
be driving as a group. The longevity industry is still
very new, but we're growing, right. I think there's a
good amount of people here, and every time I go
to a conference there's more and more people. And so

(01:49:20):
talk to your friends, talk to your politicians, talk to
people with power, because this really matters. And then the
second thing, my second ask for you is get involved
with us at a four LI We need your support.
Like I said, I don't know if we'll be able
to raise twenty million dollars here, but if we want
to get you know, a reasonable return from the government,
we need to raise money, spend it on lobbyists, spend
it on policy development, and actually, you know, come together

(01:49:42):
as a community to push this forward. So I guess
that's it.

Speaker 5 (01:49:44):
That's all.

Speaker 17 (01:49:45):
Is that good? Was all right?

Speaker 6 (01:49:46):
Perfect?

Speaker 8 (01:49:46):
Thank you, Thank you everybody, Thank you, Thank you so much.
Dylan and it's good to see what he's doing in
the USA. This is fantastic because if we get this
legislation approved in the USA, we didn't have to go
to other places, so anyway, fantastic, fantastic,

All Episodes

Episode Transcript

Popular Podcasts

Stuff You Should Know

Dateline NBC

The Burden

.css-15opob5{left:0;position:absolute;top:0.8rem;} All Episodes

.css-14f5ked{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;}TransVision Madrid 2025 Summit

Episode Transcript

Popular Podcasts

.css-r6mb8g{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:1;overflow:hidden;}Stuff You Should Know

Dateline NBC

The Burden

All Episodes

TransVision Madrid 2025 Summit

Stuff You Should Know